On December 12, we hosted an R&D Day in New York City. Alnylam management and key opinion leaders discussed the latest progress as well as plans for the future development of our RNAi therapeutics pipeline. At this event, we announced our pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.
Hepatitis B Virus
HBV is the most common serious liver infection in the world. Worldwide, 2 billion people (1 out of 3 people) have been infected with hepatitis B and 400 million people have become chronically infected.
An estimated 1 million people worldwide die each year from hepatitis B virus infection and its complications; about 5,000 of those are in the U.S. The clinical manifestations are severe. Worldwide, chronic infection with hepatitis causes 80% of all hepatocellular carcinoma (HCC) and more than 500,000 people die each year from this lethal cancer. About 5% of the population are chronic carriers of HBV, and nearly 25% of all carriers develop serious liver diseases such as chronic hepatitis, cirrhosis, and HCC. With today’s medicines, the cure rate for chronic HBV infection is less than 10%. An RNAi therapeutic inhibiting all steps of the HBV life cycle and silencing tolerogenic viral antigens has the potential to achieve a “functional cure.”
ALN-HBV for the Treatment of HBV Infection
Please read the latest press releases and data presentations for ALN-HBV here.